Isomorphic Labs Raises $5 Bn To Support AI-Based Drug Design 

Isomorphic Labs, an AI-enabled drug design and development company, has raised $5 billion to support the continued development and deployment of its AI-enabled proprietary drug design engine, IsoDDE, used to support its pipeline and partnership. The $5 billion raised in Series C financing round included continued investment from Alphabet, the parent company of Google, and follows $2.1 billion raised by the company in May (May 2026) in Series B funding. In addition, the company announced a strategic research collaboration with Merck & Co. Inc/MSD.   

Isomorphic Labs is led by Demis Hassabis, PhD and CEO, who founded the company in 2021 as a spinoff from Google DeepMind, an AI research laboratory and subsidiary of Alphabet, where he was CEO until August 2026. He is also now Chief Scientist of Alphabet and Chair of Google DeepMind, which he had earlier co-founded. He is a Co-Laureate of the 2024 Nobel Prize in Chemistry recognized for his work on protein-structure prediction using AI. 

Isomorphic Labs’ IsoDDE unifies a suite of foundational simulation AI models that natively work across multiple therapeutic areas and drug modalities. IsoDDE examines vast chemical spaces to design, refine, and deliver engineered molecules with optimal drug-like properties. Proceeds from its financing will be used to mature IsoDDE as well as expand deeper into new biology with advanced models. Proceeds will also support the company’s continued build of scalable AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials. 

Research collaboration with Merck 
Isomorphic Labs also announced that he had formed a strategic research collaboration with Merck, under which the companies will collaborate to discover therapeutic small-molecule candidates against an undisclosed oncology target. Isomorphic Labs will perform in silico predictions and deliver molecular designs by applying its proprietary drug-design engine IsoDDE incorporating select proprietary data sets supplied by Merck for the purpose of this collaboration. Merck will be responsible for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration. 

Under the agreement, Isomorphic Labs will receive an upfront payment from Merck and be eligible for payments based on the achievement of specified research, development, regulatory and commercial milestones, as well as tiered royalties on net sales. Isomorphic Labs also receives an option to co-fund development activities in return for elevated royalties. 

Participation in the Virtual Biology Initiative 
Isomorphic Labs is also participating in the Virtual Biology Initiative, a multi-institutional scientific effort led by Biohub, a nonprofit research institute combining AI and biology, to build predictive AI models of living cells. In October (October 2026), Biohub, the US Department of Energy, the National Institutes of Health and new funding partners, Google DeepMind, Meta (the parent company of Facebook), and Isomorphic Labs committed a combined $1.8 billion to build foundational data for AI models to predict and treat diseases. The funding will be used for data, computation, and new measurement technology to generate AI-ready biological data to provide an open resource for the research community to provide the foundation for greater understanding and treatment of human diseases. As part of that effort, Isomorphic Labs, Google DeepMind, and Meta are collectively investing $300 million in the Virtual Biology Initiative to create the technologies and multi-modal datasets needed to build predictive models of life. 

Source: Isomorphic Labs